Department of Pathology, Dalhousie University, Halifax, NS B3H 1X5, Canada.
Department of Pathology, Dalhousie University, Halifax, NS B3H 1X5, Canada; Department of Microbiology and Immunology, Dalhousie University, Halifax, NS B3H 1X5, Canada; Department of Biology, Dalhousie University, Halifax, NS B3H 1X5, Canada; Beatrice Hunter Cancer Research Institute, Halifax, NS B3H 1X5, Canada.
Mol Ther. 2020 Jun 3;28(6):1417-1421. doi: 10.1016/j.ymthe.2020.03.014. Epub 2020 Mar 20.
Oncolytic viruses (OVs) represent a promising new class of cancer therapeutics and cause antitumor effects by two major mechanisms: (1) directly killing cancer cells in a process known as oncolysis, or (2) initiating a powerful antitumor immune response. Interestingly, energy metabolism, within either cancer cells or immune cells, plays a pivotal role in defining the outcome of OV-mediated antitumor effects. Following therapeutic administration, OVs must hijack host cell metabolic pathways to acquire building blocks such as nucleotides, lipids, and amino acids for the process of replication that is necessary for oncolysis. Additionally, OV-stimulated antitumor immune responses are highly dependent on the metabolic state within the tumor microenvironment. Thus, metabolic reprogramming strategies bear the potential to enhance the efficacy of both OV-mediated oncolysis and antitumor immune responses.
溶瘤病毒（OVs）代表了一类有前途的新型癌症治疗药物，通过两种主要机制产生抗肿瘤作用：（1）通过称为溶瘤的过程直接杀死癌细胞，或（2）引发强大的抗肿瘤免疫反应。有趣的是，无论是癌细胞还是免疫细胞内的能量代谢，在定义 OV 介导的抗肿瘤作用的结果方面都起着关键作用。在治疗给药后，OV 必须劫持宿主细胞代谢途径以获取核苷酸、脂质和氨基酸等构建块，用于复制过程，这对于溶瘤是必要的。此外，OV 刺激的抗肿瘤免疫反应高度依赖于肿瘤微环境中的代谢状态。因此，代谢重编程策略有可能增强 OV 介导的溶瘤和抗肿瘤免疫反应的疗效。
